Investor updates Keyword Search Clear 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 Published on: 21 December 2012 Roche and PSS sign agreement to develop a fully automated workflow solution for next-generation sequencing platforms more Published on: 20 December 2012 Roche's vismodegib named Drug Discovery of the Year by the British Pharmacological Society more Published on: 14 December 2012 Roche's breast cancer treatment Perjeta receives recommendation for approval in EU more Published on: 11 December 2012 Promising data presented at ASH support continued development of multiple investigational medicines and demonstrate breadth of Roche's robust hematology pipeline more Published on: 8 December 2012 Roche reports positive studies of MabThera given by subcutaneous injection more Published on: 8 December 2012 Roche's Perjeta significantly extends survival in people with HER2-positive metastatic breast cancer more Published on: 7 December 2012 Changes in Roche Board of Directors more Published on: 29 November 2012 Roche's Zelboraf named Best New Drug at the 2012 Scrip Awards more Published on: 17 November 2012 Roche study showed that Avastin helped people with newly diagnosed glioblastoma live longer without their disease worsening when added to radiation and chemotherapy more Published on: 16 November 2012 Roche receives positive opinion from European Medicines Agency for Avastin based treatment beyond first progression in people with advanced colorectal cancer more Published on: 7 November 2012 FDA grants Roche's trastuzumab emtansine (T-DM1) Priority Review for HER2-positive metastatic breast cancer more Published on: 5 November 2012 Roche`s aleglitazar renal safety study AleNephro meets primary endpoint more Published on: 31 October 2012 Roche medicine Avastin receives EU approval for the treatment of women with recurrent, platinum-sensitive ovarian cancer more Published on: 16 October 2012 Roche Group posts strong sales growth in the third quarter more Published on: 15 October 2012 FDA approves expanded indication for ACTEMRA in Rheumatoid Arthritis more Published on: 9 October 2012 Reminder: Invitation to Roche's Third Quarter Sales 2012 Conference Call more Published on: 5 October 2012 Anti-Cancer Agent “Avastin®,” Application for Approval of Additional Indication of Ovarian Cancer more Published on: 2 October 2012 Reminder - Roche conference call for investors and analysts from ESMO 2012 more Published on: 1 October 2012 Roche's trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancer more Published on: 1 October 2012 Final analysis of Phase III HERA trial confirmed one year of Herceptin treatment as standard of care in early-stage HER2-positive breast cancer more Published on: 24 September 2012 ESMO 2012: Roche underscores leadership in oncology with new data in HER2 positive breast cancer and skin cancer more Published on: 21 September 2012 Roche's Avastin receives positive opinion from EU authority for the treatment of women with recurrent, platinum-sensitive ovarian cancer more Published on: 21 September 2012 Roche conference call for investors and analysts from ESMO 2012 more Published on: 19 September 2012 Anti-Cancer Agent “Avastin®,” Application for Approval of Additional Indication of Recurrent Glioblastoma more Published on: 18 September 2012 Invitation to Roche's Third Quarter Sales 2012 Conference Call more Published on: 13 September 2012 Roche leads healthcare sector in key sustainability index for fourth consecutive year more Published on: 5 September 2012 Roche committed to innovation and growth more Published on: 28 August 2012 Changes to the Roche Corporate Executive Committee more Published on: 27 August 2012 New data from Phase III EMILIA study showed Roche's trastuzumab emtansine (T-DM1) significantly improved survival of people with HER2-positive metastatic breast cancer more Published on: 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema more Published on: 10 August 2012 Roche study showed that adding Avastin to radiation and chemotherapy significantly extended the time people with an aggressive form of brain cancer lived without their disease worsening more Published on: 27 July 2012 FDA advisory committee unanimously recommends approval of Lucentis for treatment of diabetic macular edema (DME) more Published on: 27 July 2012 Roche reports second positive study of RoACTEMRA given by subcutaneous injection to patients with rheumatoid arthritis more Published on: 26 July 2012 Full reconciliation of Chugai half-year 2012 results into IFRS more Published on: 26 July 2012 FDA clears Roche's vitamin D laboratory test more Published on: 26 July 2012 Roche posts strong operating first-half results; on track to meet 2012 guidance more Published on: 19 July 2012 Reminder: Invitation to Roche's Half Year Results for 2012 more Published on: 19 July 2012 FDA clears Accu-Chek Combo system - Roche's new interactive insulin pump system for people with diabetes more Published on: 27 June 2012 Invitation to Roche's Half Year Results for 2012 more Published on: 26 June 2012 Roche to streamline research and development activities more Published on: 26 June 2012 Anti-Cancer Agent “Tarceva®”, Application for Approval of Additional Indication of Non-Small Cell Lung Cancer (First Line Therapy) more Published on: 22 June 2012 New data from Phase III study showed that people with HER2-positive metastatic breast cancer lived longer with Roche's Perjeta more Published on: 19 June 2012 Roche and Seaside Therapeutics Announce Landmark Alliance to Advance Novel Treatments for Fragile X Syndrome and Autism Spectrum Disorders more Published on: 11 June 2012 FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer more Published on: 6 June 2012 Roche's RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy more Published on: 3 June 2012 Roche's targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III trial more Published on: 3 June 2012 Roche data showed that people with metastatic colorectal cancer lived longer when they continued on Avastin plus chemotherapy more Published on: 2 June 2012 Roche study showed that adding Avastin to chemotherapy cut the risk of the disease getting worse in difficult-to-treat recurrent ovarian cancer by half more Published on: 1 June 2012 Reminder: Roche conference call for investors and analysts from EULAR 2012 more Published on: 30 May 2012 Reminder: Roche Analyst Event at ASCO 2012 more Published on: 25 May 2012 Roche Analyst Event at ASCO 2012 more Published on: 25 May 2012 New Drug Application Filed for Anti-Cancer Agent “Pertuzumab” for the Treatment of HER2-Positive Metastatic or Recurrent Breast Cancer more Published on: 24 May 2012 Invitation Roche Investor Day 2012 more Published on: 16 May 2012 Roche will report new data on important progress for people with advanced cancers at ASCO 2012 more Published on: 10 May 2012 Roche conference call for investors and analysts from EULAR 2012 more Published on: 7 May 2012 Roche provides update on Phase III study of dalcetrapib more Published on: 3 May 2012 Roche Analyst Event at ASCO 2012 more Published on: 3 May 2012 Roche reports positive study of RoACTEMRA given by subcutaneous injection more Published on: 19 April 2012 Roche reports high rates of sustained viral clearance with investigational hepatitis C treatment danoprevir more Published on: 18 April 2012 Roche decides not to extend its tender offer for Illumina, Inc. more Published on: 12 April 2012 Roche on track for full-year targets – good sales growth in first quarter more Published on: 12 April 2012 Roche issues statement regarding Illumina offer more Published on: 11 April 2012 Roche sends open letter to Illumina shareholders more Published on: 6 April 2012 Roche disappointed with ISS recommendation more Published on: 4 April 2012 Roche sends second letter to Illumina shareholders more Published on: 3 April 2012 Reminder: Invitation to Roche's First Quarter Sales 2012 Conference Call more Published on: 3 April 2012 Roche disappointed by Illumina, Inc.'s Board of Directors' rejection more Published on: 30 March 2012 Roche's trastuzumab emtansine (T-DM1) showed positive Phase III results in HER2-positive metastatic breast cancer more Published on: 29 March 2012 Roche increases offer price for Illumina shares to US$ 51.00 per share more Published on: 26 March 2012 Roche extends tender offer for Illumina more Published on: 23 March 2012 Roche's Herceptin given by subcutaneous injection offers greater convenience to patients and reduces overall healthcare costs compared to standard IV infusion more Published on: 20 March 2012 Roche files definitive proxy statement more Published on: 13 March 2012 Roche receives request for additional information from the Federal Trade Commission more Published on: 12 March 2012 Invitation to Roche's First Quarter Sales 2012 Conference Call more Published on: 12 March 2012 Second Transnet-Phelophepa Healthcare Train inaugurated in South Africa more Published on: 6 March 2012 Roche Annual General Meeting 2012 more Published on: 2 March 2012 Roche's RoACTEMRA monotherapy showed superior improvement in rheumatoid arthritis signs and symptoms versus adalimumab monotherapy more Published on: 27 February 2012 Roche extends tender offer for Illumina more Published on: 20 February 2012 Roche's Zelboraf receives EU approval for the treatment of people with deadly form of skin cancer more Published on: 8 February 2012 FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer more Published on: 8 February 2012 Roche disappointed by the actions of Illumina, Inc.'s Board of Directors more Published on: 1 February 2012 Full reconciliation of Chugai 2011 results into IFRS more Published on: 1 February 2012 Roche in 2011: Strong results and positive outlook more Published on: 31 January 2012 Roche to nominate slate of independent directors for election at Illumina, Inc.'s 2012 annual meeting more Published on: 30 January 2012 FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma more Published on: 27 January 2012 Roche commences tender offer for Illumina, Inc. for $44.50 per share in cash more Published on: 27 January 2012 Roche responds to adoption of shareholder rights plan by Illumina Board of Directors more Published on: 26 January 2012 Avastin-based regimen extends survival when continued beyond initial treatment in patients with metastatic colorectal cancer more Published on: 25 January 2012 Roche offers to acquire all outstanding shares of Illumina, Inc. to further strengthen its leading role in diagnostics more Published on: 18 January 2012 Reminder: Invitation to Roche's Full Year Results for 2011 more Published on: 11 January 2012 Roche receives clearance from the U.S. Food and Drug Administration for the new Accu-Chek Nano SmartView blood glucose monitoring system more Published on: 3 January 2012 Invitation to Roche's Full Year Results for 2011 more
Published on: 21 December 2012 Roche and PSS sign agreement to develop a fully automated workflow solution for next-generation sequencing platforms more
Published on: 20 December 2012 Roche's vismodegib named Drug Discovery of the Year by the British Pharmacological Society more
Published on: 14 December 2012 Roche's breast cancer treatment Perjeta receives recommendation for approval in EU more
Published on: 11 December 2012 Promising data presented at ASH support continued development of multiple investigational medicines and demonstrate breadth of Roche's robust hematology pipeline more
Published on: 8 December 2012 Roche reports positive studies of MabThera given by subcutaneous injection more
Published on: 8 December 2012 Roche's Perjeta significantly extends survival in people with HER2-positive metastatic breast cancer more
Published on: 17 November 2012 Roche study showed that Avastin helped people with newly diagnosed glioblastoma live longer without their disease worsening when added to radiation and chemotherapy more
Published on: 16 November 2012 Roche receives positive opinion from European Medicines Agency for Avastin based treatment beyond first progression in people with advanced colorectal cancer more
Published on: 7 November 2012 FDA grants Roche's trastuzumab emtansine (T-DM1) Priority Review for HER2-positive metastatic breast cancer more
Published on: 5 November 2012 Roche`s aleglitazar renal safety study AleNephro meets primary endpoint more
Published on: 31 October 2012 Roche medicine Avastin receives EU approval for the treatment of women with recurrent, platinum-sensitive ovarian cancer more
Published on: 15 October 2012 FDA approves expanded indication for ACTEMRA in Rheumatoid Arthritis more
Published on: 9 October 2012 Reminder: Invitation to Roche's Third Quarter Sales 2012 Conference Call more
Published on: 5 October 2012 Anti-Cancer Agent “Avastin®,” Application for Approval of Additional Indication of Ovarian Cancer more
Published on: 2 October 2012 Reminder - Roche conference call for investors and analysts from ESMO 2012 more
Published on: 1 October 2012 Roche's trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancer more
Published on: 1 October 2012 Final analysis of Phase III HERA trial confirmed one year of Herceptin treatment as standard of care in early-stage HER2-positive breast cancer more
Published on: 24 September 2012 ESMO 2012: Roche underscores leadership in oncology with new data in HER2 positive breast cancer and skin cancer more
Published on: 21 September 2012 Roche's Avastin receives positive opinion from EU authority for the treatment of women with recurrent, platinum-sensitive ovarian cancer more
Published on: 19 September 2012 Anti-Cancer Agent “Avastin®,” Application for Approval of Additional Indication of Recurrent Glioblastoma more
Published on: 13 September 2012 Roche leads healthcare sector in key sustainability index for fourth consecutive year more
Published on: 27 August 2012 New data from Phase III EMILIA study showed Roche's trastuzumab emtansine (T-DM1) significantly improved survival of people with HER2-positive metastatic breast cancer more
Published on: 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema more
Published on: 10 August 2012 Roche study showed that adding Avastin to radiation and chemotherapy significantly extended the time people with an aggressive form of brain cancer lived without their disease worsening more
Published on: 27 July 2012 FDA advisory committee unanimously recommends approval of Lucentis for treatment of diabetic macular edema (DME) more
Published on: 27 July 2012 Roche reports second positive study of RoACTEMRA given by subcutaneous injection to patients with rheumatoid arthritis more
Published on: 26 July 2012 Roche posts strong operating first-half results; on track to meet 2012 guidance more
Published on: 19 July 2012 FDA clears Accu-Chek Combo system - Roche's new interactive insulin pump system for people with diabetes more
Published on: 26 June 2012 Anti-Cancer Agent “Tarceva®”, Application for Approval of Additional Indication of Non-Small Cell Lung Cancer (First Line Therapy) more
Published on: 22 June 2012 New data from Phase III study showed that people with HER2-positive metastatic breast cancer lived longer with Roche's Perjeta more
Published on: 19 June 2012 Roche and Seaside Therapeutics Announce Landmark Alliance to Advance Novel Treatments for Fragile X Syndrome and Autism Spectrum Disorders more
Published on: 11 June 2012 FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer more
Published on: 6 June 2012 Roche's RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy more
Published on: 3 June 2012 Roche's targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III trial more
Published on: 3 June 2012 Roche data showed that people with metastatic colorectal cancer lived longer when they continued on Avastin plus chemotherapy more
Published on: 2 June 2012 Roche study showed that adding Avastin to chemotherapy cut the risk of the disease getting worse in difficult-to-treat recurrent ovarian cancer by half more
Published on: 1 June 2012 Reminder: Roche conference call for investors and analysts from EULAR 2012 more
Published on: 25 May 2012 New Drug Application Filed for Anti-Cancer Agent “Pertuzumab” for the Treatment of HER2-Positive Metastatic or Recurrent Breast Cancer more
Published on: 16 May 2012 Roche will report new data on important progress for people with advanced cancers at ASCO 2012 more
Published on: 3 May 2012 Roche reports positive study of RoACTEMRA given by subcutaneous injection more
Published on: 19 April 2012 Roche reports high rates of sustained viral clearance with investigational hepatitis C treatment danoprevir more
Published on: 12 April 2012 Roche on track for full-year targets – good sales growth in first quarter more
Published on: 3 April 2012 Reminder: Invitation to Roche's First Quarter Sales 2012 Conference Call more
Published on: 30 March 2012 Roche's trastuzumab emtansine (T-DM1) showed positive Phase III results in HER2-positive metastatic breast cancer more
Published on: 29 March 2012 Roche increases offer price for Illumina shares to US$ 51.00 per share more
Published on: 23 March 2012 Roche's Herceptin given by subcutaneous injection offers greater convenience to patients and reduces overall healthcare costs compared to standard IV infusion more
Published on: 13 March 2012 Roche receives request for additional information from the Federal Trade Commission more
Published on: 12 March 2012 Second Transnet-Phelophepa Healthcare Train inaugurated in South Africa more
Published on: 2 March 2012 Roche's RoACTEMRA monotherapy showed superior improvement in rheumatoid arthritis signs and symptoms versus adalimumab monotherapy more
Published on: 20 February 2012 Roche's Zelboraf receives EU approval for the treatment of people with deadly form of skin cancer more
Published on: 8 February 2012 FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer more
Published on: 8 February 2012 Roche disappointed by the actions of Illumina, Inc.'s Board of Directors more
Published on: 31 January 2012 Roche to nominate slate of independent directors for election at Illumina, Inc.'s 2012 annual meeting more
Published on: 30 January 2012 FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma more
Published on: 27 January 2012 Roche commences tender offer for Illumina, Inc. for $44.50 per share in cash more
Published on: 27 January 2012 Roche responds to adoption of shareholder rights plan by Illumina Board of Directors more
Published on: 26 January 2012 Avastin-based regimen extends survival when continued beyond initial treatment in patients with metastatic colorectal cancer more
Published on: 25 January 2012 Roche offers to acquire all outstanding shares of Illumina, Inc. to further strengthen its leading role in diagnostics more
Published on: 11 January 2012 Roche receives clearance from the U.S. Food and Drug Administration for the new Accu-Chek Nano SmartView blood glucose monitoring system more